Biosynthesis of heparin proteoglycan (serglycin)

肝素是一种具有抗凝活性的生物制品。它广泛用于心肺手术、血液透析和动脉/静脉血栓的治疗。涉及肝素加工的生物合成过程，特别是在高尔基体中完成后直至最终产物储存在分泌颗粒中的碳水化合物链的生物合成过程尚未阐明。本研究试图对这一过程进行详细的分析，并得出结论，“肝素酶”是这一过程中的关键酶，新产生的肝素链的非还原末端具有特定的功能。

Heparin is a biological product having anticoagulant activity. It is widely used in heart-lung surgeries, hemodialysis, and in the treatment of arterial/venous thromboses. Biosynthetic processes involved in the processing of heparin, especially that of carbohydrate chains after completion in Golgi until the storage of the final products in secretion granules, have not been elucidated. The current research attempted to analyze this processes in detail, and has reached a conclusion that the “heparanase” is the key enzyme in this process and the newly generated non-reducing ends of heparin chains weresuggested to have specific functions.